Surged 390.02% but has concerns about potential fraud, extreme volatility, and high risk. Investors are advised to exercise extreme caution.

Presents a high-risk, high-reward binary event scenario dependent on an upcoming FDA decision for its drug Deremyocel. There are conflicting narratives: a bearish view alleging data manipulation versus the company's bullish presentation of statistically significant trial results that they believe address prior FDA concerns.

The speaker is short the stock, calling it a 'shitty little biotech company' and believes its technology is fraudulent ('it's all cap'), expecting a price collapse on upcoming clinical trial data.

The speaker is short the stock with strong bearish conviction, betting that the upcoming HOPE-III clinical trial data will be negative. A slight delay in the data release reinforces his bearish thesis.

The speaker is extremely bearish, calling it a 'short' and advising to 'sell it all' based on his belief that the company's underlying science is nonsensical.

Speaker is building a short position, potentially via November $4 puts, based on a valuation analysis suggesting the stock could trade down to its cash levels, around $1.80 per share.

Considered a 'good short' as the speaker believes its drug 'doesn't do anything' and expects negative data in two weeks, with a potential downside of ~50% to around $2.14.

Identified as a high-conviction short idea. The speaker is anticipating its HOPE-3 clinical trial will fail, which would be a 'profit extravaganza' for short-sellers.

The speaker is bearish and explicitly states that 'Capper is a short.'

The speaker was extremely critical, highlighting that the FDA rejected their drug and that the stock may be trading on hype from a 'big retail fan base' rather than fundamentals.